Marinomed Biotech AG logo

MARI - Marinomed Biotech AG Share Price

€125 2.0  1.6%

Last Trade - 11:37am

Small Cap
Market Cap £155.9m
Enterprise Value £159.0m
Revenue £6.98m
Position in Universe 663rd / 1054
Unlock MARI Revenue
Relative Strength (%)
1m -10.4%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -16.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 2.61 4.81 4.67 6.14 8.12 14.7 63.4 +32.8%
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020,Marinomed Biotech AG revenues increased 32% to EUR8.1M. Netloss decreased 17% to EUR6M. Revenues reflect Marinosolvsegment increase from EUR15K to EUR39K, Other EuropeanCountries segment increase of 76% to EUR5.3M, Non EuropeanCountries segment increase of 27% to EUR2.4M. Lower netloss reflects Other Income increase of 71% to EUR1.2M(income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


MARI Revenue Unlock MARI Revenue

Net Income

MARI Net Income Unlock MARI Revenue

Normalised EPS

MARI Normalised EPS Unlock MARI Revenue

PE Ratio Range

MARI PE Ratio Range Unlock MARI Revenue

Dividend Yield Range

MARI Dividend Yield Range Unlock MARI Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
MARI EPS Forecasts Unlock MARI Revenue
Profile Summary

Marinomed Biotechnologie GmbH is an Austria-based biopharmaceutical company engaged in the pharmaceuticals industry. The Company develops anti-viral and immunological therapies, such as nasal sprays, using the antiviral respiratory technology platform MAVIREX, which target more than 200 different respiratory virus strains based on Carragelose, a red algae derived polymer. The company also offers products for the treatment of influenza, combination products for asthmatics, and others. In addition, the Company develops treatments against type I allergy and autoimmune diseases. The Company operates as a spin-off from the Veterinary University of Vienna.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated December 31, 2006
Public Since February 1, 2019
No. of Shareholders: n/a
No. of Employees: 37
Sector Healthcare
Industry Pharmaceuticals
Exchange Vienna Stock Exchange
Shares in Issue 1,474,731
Free Float (0.0%)
Eligible for
View larger map
Address Veterinaerplatz 1, WIEN, 1210, Austria
Web https://www.marinomed.com/
Phone +43 1 250774460
Contact ()
Auditors Bdo Austria GmbH Wirtschaftsprufungs Und Steuerberatungsgese
MARI Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for MARI
Upcoming Events for MARI
Friday 17th September, 2021 Estimate
Marinomed Biotech AG Annual Shareholders Meeting
Frequently Asked Questions for Marinomed Biotech AG
What is the Marinomed Biotech AG share price?

As of 11:37am, shares in Marinomed Biotech AG are trading at €125, giving the company a market capitalisation of £155.9m. This share price information is delayed by 15 minutes.

How has the Marinomed Biotech AG share price performed this year?

Shares in Marinomed Biotech AG are currently trading at €125 and the price has moved by 23% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Marinomed Biotech AG price has moved by -3.65% over the past year.

What are the analyst and broker recommendations for Marinomed Biotech AG?

Of the analysts with advisory recommendations for Marinomed Biotech AG, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Marinomed Biotech AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Marinomed Biotech AG next release its financial results?

Marinomed Biotech AG is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Marinomed Biotech AG dividend yield?

Marinomed Biotech AG does not currently pay a dividend.

Does Marinomed Biotech AG pay a dividend?

Marinomed Biotech AG does not currently pay a dividend.

When does Marinomed Biotech AG next pay dividends?

Marinomed Biotech AG does not currently pay a dividend.

How do I buy Marinomed Biotech AG shares?

To buy shares in Marinomed Biotech AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Marinomed Biotech AG?

Shares in Marinomed Biotech AG are currently trading at €125, giving the company a market capitalisation of £155.9m.

Where are Marinomed Biotech AG shares listed? Where are Marinomed Biotech AG shares listed?

Here are the trading details for Marinomed Biotech AG:

Country of listing: Austria
Exchange: VIE
Ticker Symbol: MARI
What kind of share is Marinomed Biotech AG?

Based on an overall assessment of its quality, value and momentum, Marinomed Biotech AG is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Marinomed Biotech AG share price forecast 2021?

Shares in Marinomed Biotech AG are currently priced at €125. At that level they are trading at 36.77% discount to the analyst consensus target price of 0.00.

Analysts covering Marinomed Biotech AG currently have a consensus Earnings Per Share (EPS) forecast of -3.593 for the next financial year.

How can I tell whether the Marinomed Biotech AG share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Marinomed Biotech AG. Over the past six months, the relative strength of its shares against the market has been -5.22%. At the current price of €125, shares in Marinomed Biotech AG are trading at 3.75% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Marinomed Biotech AG PE Ratio?

We were not able to find PE ratio data for Marinomed Biotech AG.

Who are the key directors of Marinomed Biotech AG?

Marinomed Biotech AG's management team is headed by:

Andreas Grassauer - CMG
Eva Prieschl-Grassauer - CSO
Pascal Schmidt - CFO
Helmut Baranyovszki - FID
Renate Moser - VBD
Simon Nebel - CSU
Ute Lassnig - VSU
Karl Lankmayr - SUB
Gernot Hofer - SUB
Brigitte Ederer - SUB
Who are the major shareholders of Marinomed Biotech AG?

Here are the top five shareholders of Marinomed Biotech AG based on the size of their shareholding:

Abdulmohsen (Al Sheikh) & Mohammed (AlSheikh) Individual Investor
Percentage owned: 13.86% (204k shares)
Erste Asset Management GmbH Investment Advisor
Percentage owned: 10.3% (152k shares)
Unger (Hermann) Individual Investor
Percentage owned: 8.47% (125k shares)
Prieschl-Grassauer (Eva) Individual Investor
Percentage owned: 8.26% (122k shares)
Grassauer (Andreas) Individual Investor
Percentage owned: 8.26% (122k shares)
Similar to MARI
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.